News | Radiopharmaceuticals and Tracers | November 15, 2022

Full-scale CDMO services for collaborating companies designed to facilitate radiopharmaceutical development and commercialization in complex, highly regulated radiopharmaceutical sector 

NorthStar Medical Radioisotopes’ Radiopharmaceutical CDMO in Beloit, Wis. (artist rendering). Upon completion, NorthStar will be first and only U.S. company housing commercial-scale, multi-radioisotope production and radiopharmaceutical development services on the same campus, enabling collaborating companies to realize logistical, regulatory and cost benefits. (Photo: Business Wire)

NorthStar Medical Radioisotopes’ Radiopharmaceutical CDMO in Beloit, Wis. (artist rendering). Upon completion, NorthStar will be first and only U.S. company housing commercial-scale, multi-radioisotope production and radiopharmaceutical development services on the same campus, enabling collaborating companies to realize logistical, regulatory and cost benefits. (Photo: Business Wire) 


November 15, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced a significant expansion of its business platform with the formation of a new, patient-focused Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit. Based on the success of its diagnostic imaging and therapeutic radioisotope production programs, NorthStar has created the services unit to further advance development and commercialization of radiopharmaceuticals to treat patients who have cancer and other serious diseases. The CDMO will provide collaborator companies with a full range of customized radiopharmaceutical development and commercialization services, and serve NorthStar in progressing its own radiopharmaceutical programs. Ground has been broken on a new facility, located alongside production facilities on the Company’s Beloit, Wis. campus. Upon completion, NorthStar will be the first and only U.S. company housing commercial-scale, multi-radioisotope production and radiopharmaceutical development services on the same campus, enabling collaborator companies to realize logistical, regulatory and cost benefits. 

“Establishing this new radiopharmaceutical CDMO services unit at NorthStar marks an important inflection point in our growth plan to facilitate efficient patient supply of game-changing radiopharmaceuticals,” said Stephen Merrick, Chief Executive Officer of NorthStar Medical Radioisotopes. “NorthStar’s industry-leading reputation is grounded in technological innovation, successful execution and proven expertise. Our track record of success includes production and expanded capacity of U.S.-produced, non-uranium based molybdenum-99 (Mo-99) for use in diagnostic imaging. We are poised to be the first commercial-scale producer of non-carrier added (n.c.a.) therapeutic radioisotopes actinium-225 (Ac-225) and copper-67 (Cu-67) using advanced, environmentally preferable electron accelerator technology. With our depth and breadth of technical knowledge in the development and production of medical radioisotopes, we are now expanding to help companies progress their own radiopharmaceutical development programs. NorthStar’s CDMO will enable us to share our radiopharmaceutical development and commercialization expertise with pharmaceutical or biotechnology companies that may require additional infrastructure, resources or the specialized knowledge required for complex radiopharmaceutical development, to help them develop and deliver products with the potential to improve care for even more patients with serious disease.” 

“We are excited that NorthStar will be able to offer a full spectrum of radiopharmaceutical CDMO services to facilitate the radiopharmaceutical drug development process,” said Frank Scholz, Ph.D., President and Chief Operating Officer of NorthStar Medical Radioisotopes. “We plan to collaborate with pharmaceutical and biotechnology companies to provide customized input and support across all phases of program development, from early stage through commercialization and product life cycle management. NorthStar’s radiopharmaceutical CDMO services will be customized to accommodate each customer’s needs and in compliance with rigorous regulations and attention to safety. They will include radionuclide procurement and formulation, dedicated suites for compounding and filling operations, quality assurance and quality control, analytical services, regulatory support, scale-up and commercialization activities and logistical support with packaging and shipping. NorthStar’s highly talented workforce possesses the specialized expertise to help support our radiopharmaceutical CDMO activities, and we plan to hire additional employees in association with this expansion. We have begun design, construction and fitting-out of clean rooms, laboratories and other required infrastructure for the dedicated 36,000 square foot facility, and expect that it should be available to deliver services in late 2024, pending appropriate licensure and regulatory approvals.” 

For more information: www.northstarnm.com 

Related Radioisotope Content:    

NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-Emitting Therapeutic Radioisotope Actinium-225 (Ac-225)  

NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)    

Update on HFR Reactor Outage – Medical Isotope Supply Returning to Normal    

Update on Unplanned Outage of the HFR Reactor    

SNMMI Issues Alert That HFR Outage Will Impact Isotope Supply    

NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals    

How Nuclear Fusion is Revolutionizing Medical Isotope Production    

FDA Approves Additional Molybdenum-99 (Mo-99) Filling Lines at NorthStar Medical Radioisotopes    

Medical Isotope Industry Opposes Export of Highly Enriched Uranium for IRE    

IBA and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Tc-99m 


Related Content

News | Proton Therapy

November 25, 2022 — Researchers at the University of Wisconsin–Madison, the first U.S. clinical evaluation site for GE ...

Time November 25, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

November 21, 2022 — You can keep your best guesses. Engineers at Rice University’s George R. Brown School of Engineering ...

Time November 21, 2022
arrow
News | RSNA

November 21, 2022 — Taking anti-inflammatory pain relievers like ibuprofen and naproxen for osteoarthritis may worsen ...

Time November 21, 2022
arrow
News | Radiopharmaceuticals and Tracers

Nov. 4, 2022 — On October 28, the Nuclear Medicine Europe Emergency Response Team issued a statement about mechanical ...

Time November 05, 2022
arrow
News | PET Imaging

October 25, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 25, 2022
arrow
News | PET Imaging

October 20, 2022 — A new highly selective PET imaging agent can detect the presence of overexpressed monoamine oxidase-B ...

Time October 20, 2022
arrow
News | SPECT-CT

October 18, 2022 — Spectrum Dynamics announced its newest development in digital nuclear medicine imaging: the ...

Time October 18, 2022
arrow
News | Quality Assurance (QA)

October 7, 2022 — Mirion Technologies, Inc., a global provider of radiation detection, measurement, analysis and ...

Time October 07, 2022
arrow
News | Radiopharmaceuticals and Tracers

October 6, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time October 06, 2022
arrow
Subscribe Now